- Home
- SORA vs FBIO Comparison
SORA vs FBIO Comparison
Compare SORA & FBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SORA | FBIO |
|---|---|---|
| Founded | 2001 | 2006 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.0M | 113.9M |
| IPO Year | 2025 | N/A |
Fundamental Metrics
Financial Performance| Metric | SORA | FBIO |
|---|---|---|
| Price | $3.17 | $4.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 9.5K | ★ 560.7K |
| Earning Date | 05-12-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $14,081,504.00 | ★ $62,303,000.00 |
| Revenue This Year | N/A | $29.71 |
| Revenue Next Year | N/A | $49.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.80 | $1.33 |
| 52 Week High | $14.15 | $4.20 |
Technical Indicators
Market Signals| Indicator | SORA | FBIO |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 75.05 |
| Support Level | N/A | $3.54 |
| Resistance Level | N/A | $3.81 |
| Average True Range (ATR) | 0.00 | 0.24 |
| MACD | 0.00 | 0.04 |
| Stochastic Oscillator | 0.00 | 94.82 |
Price Performance
Historical ComparisonAbout SORA Top Win International Limited Ordinary Shares
AsiaStrategy is a wholesaler engaged in trading, distribution, and retail of luxury watches of international brands. The Group sources its luxury watches from Europe, Singapore, Japan, and Hong Kong, then sells the goods to retail sellers and other distributors in the watch industry.
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.